Dedicated to Global Health, MedinCell is an independent, self-funded and employee-owned company. Free of external financial interests, we incorporate scientific and humanitarian goals into our business as long-term strategic objectives. As a hybrid organization, we work simultaneously on for-profit and non-profit activities with our high-value network of partners.

Skills and commitment of our employees from all around the world are the core value of MedinCell. To attract and retain the best talents in the biotechnological and pharmaceutical industry, we offer a proactive and creative environment where individuals can participate and contribute to the overall success of the company.  


Our values

Power of the Group


Purposeful Innovation

Trust and Respect

Transparency and Directness



The Story

MedinCell founded

2002 > 2010
Research & Development

December 2010
Patent application for the BEPO™ drug delivery technology filed in 70 countries

January 2011
Launch of the BEPO™ technology platform

“On the Rise Company” – Drug Delivery Partnerships (Miami)

2012 – present
Collaboration agreements in many fields: contraception, schizophrenia, depression, obstetrics, intra-articular, intravitreal, HIV, parasitology, pain, anaesthetic, etc.

Start of humanitarian collaborations

November 2013
1st multi-API agreement with a major pharma

May 2015
BEPO™ US Patent issued

August 2015
Joint Venture CM Biomaterials formed with Corbion for polymer supply

November 2015
Multi-API agreement with Sandoz, a Novartis Subsidiary

June 2016
Second facility in Jacou – France


Our locations

MedinCell S.A.
3 rue des Frères Lumière
34830 Jacou

MedinCell Corporation
One Broadway, 14th Floor
Cambridge, MA 02142